Edwards Lifesciences Corporation Increase (Decrease) in Notes Receivables
Edwards Lifesciences Corporation (EW) reported Increase (Decrease) in Notes Receivables of $52.30 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInNotesReceivables · last filed 2023-02-13
- Edwards Lifesciences Corporation increase (decrease) in notes receivables for the quarter ending 2022-03-31 was $10.50M, a 191.67% increase year-over-year.
- Edwards Lifesciences Corporation increase (decrease) in notes receivables for the quarter ending 2021-12-31 was $1.50M, a 200.00% increase year-over-year.
- Edwards Lifesciences Corporation increase (decrease) in notes receivables for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Edwards Lifesciences Corporation increase (decrease) in notes receivables for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- Edwards Lifesciences Corporation increase (decrease) in notes receivables for fiscal 2022 was $52.30M, a 925.49% increase from fiscal 2021.
- Edwards Lifesciences Corporation increase (decrease) in notes receivables for fiscal 2021 was $5.10M, a 81.11% decline from fiscal 2020.
- Edwards Lifesciences Corporation increase (decrease) in notes receivables for fiscal 2020 was $27.00M, a 109.30% increase from fiscal 2019.
- Edwards Lifesciences Corporation increase (decrease) in notes receivables for fiscal 2019 was $12.90M, a 2050.00% increase from fiscal 2018.
| Period end | Increase (Decrease) in Notes Receivables 3 month | Increase (Decrease) in Notes Receivables 6 month | Increase (Decrease) in Notes Receivables 9 month | Increase (Decrease) in Notes Receivables 12 month | Increase (Decrease) in Notes Receivables 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | $52.30M 10-K · filed 2023-02-13 | ||||
| 2022-03-31 | $10.50M 10-Q · filed 2022-04-28 | $12.00M derived: sum of 2 quarters · filed 2023-02-13 | $12.00M derived: sum of 3 quarters · filed 2023-02-13 | $12.00M derived: sum of 4 quarters · filed 2023-02-13 | |
| 2021-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-13 | $1.50M derived: sum of 2 quarters · filed 2023-02-13 | $1.50M derived: sum of 3 quarters · filed 2023-02-13 | $5.10M 10-K · filed 2023-02-13 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | $0.00 derived: sum of 2 quarters · filed 2021-10-29 | $3.60M 10-Q · filed 2021-10-29 | $4.10M derived: sum of 4 quarters · filed 2023-02-13 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $3.60M 10-Q · filed 2021-07-30 | $4.10M derived: sum of 3 quarters · filed 2023-02-13 | $8.70M derived: sum of 4 quarters · filed 2023-02-13 | |
| 2021-03-31 | $3.60M 10-Q · filed 2022-04-28 | $4.10M derived: sum of 2 quarters · filed 2023-02-13 | $8.70M derived: sum of 3 quarters · filed 2023-02-13 | $14.00M derived: sum of 4 quarters · filed 2023-02-13 | |
| 2020-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-13 | $5.10M derived: sum of 2 quarters · filed 2023-02-13 | $10.40M derived: sum of 3 quarters · filed 2023-02-13 | $27.00M 10-K · filed 2023-02-13 | |
| 2020-09-30 | $4.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | $9.90M derived: sum of 2 quarters · filed 2021-10-29 | $26.50M 10-Q · filed 2021-10-29 | $31.00M derived: sum of 4 quarters · filed 2022-02-14 | |
| 2020-06-30 | $5.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $21.90M 10-Q · filed 2021-07-30 | $26.40M derived: sum of 3 quarters · filed 2022-02-14 | $29.40M derived: sum of 4 quarters · filed 2022-02-14 | |
| 2020-03-31 | $16.60M 10-Q · filed 2021-04-28 | $21.10M derived: sum of 2 quarters · filed 2022-02-14 | $24.10M derived: sum of 3 quarters · filed 2022-02-14 | $28.80M derived: sum of 4 quarters · filed 2022-02-14 | |
| 2019-12-31 | $4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-14 | $7.50M derived: sum of 2 quarters · filed 2022-02-14 | $12.20M derived: sum of 3 quarters · filed 2022-02-14 | $12.90M 10-K · filed 2022-02-14 | |
| 2019-09-30 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-26 | $7.70M derived: sum of 2 quarters · filed 2020-10-26 | $8.40M 10-Q · filed 2020-10-26 | ||
| 2019-06-30 | $4.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-27 | $5.40M 10-Q · filed 2020-07-27 | |||
| 2019-03-31 | $700.00K 10-Q · filed 2020-04-28 | ||||
| 2018-12-31 | $600.00K 10-K · filed 2021-02-12 | $0.00 10-K · filed 2019-02-15 | |||
| 2017-12-31 | $18.90M 10-K · filed 2019-02-15 | ||||
| 2016-12-31 | $0.00 10-K · filed 2019-02-15 | ||||
| 2015-12-31 | $0.00 10-K · filed 2018-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |